探讨α-亚麻酸与左卡尼汀联合补充对偏头痛女性炎症状态、氧化应激、临床症状、心理健康及生活质量的影响:一项随机三盲安慰剂对照试验方案
本研究为平行、随机、三盲、安慰剂对照临床试验方案,纳入80名20至50岁偏头痛女性,干预组(n=40)每日同时补充1000毫克亚麻籽油和500毫克左卡尼汀,对照组(n=40)每日同时服用1000毫克石蜡油和500毫克麦芽糊精安慰剂,为期12周。主要结局包括偏头痛临床特征及血清CRP、TAC、NO、MDA、SOD水平,次要结局包括心理健康、睡眠质量和生活质量。
要点
- 80名20至50岁偏头痛女性随机分为干预组(n=40)和对照组(n=40),疗程12周。
- 干预组每日补充1000毫克亚麻籽油和500毫克左卡尼汀,对照组使用外观一致的安慰剂。
- 主要结局为偏头痛发作频率、严重程度、持续时间及血清CRP、TAC、NO、MDA、SOD变化。
核心结论
- 研究旨在评估α-亚麻酸与左卡尼汀联合补充对偏头痛患者的潜在获益,假设两者因抗炎和抗氧化特性可能产生协同有益作用。
研究设计与样本
- 平行、随机、三盲、安慰剂对照临床试验方案,计划纳入80名20至50岁偏头痛女性。
- 干预组(n=40)每日同时接受1000毫克亚麻籽油和500毫克左卡尼汀,对照组(n=40)每日同时接受1000毫克石蜡油和500毫克麦芽糊精安慰剂,疗程均为12周。
主要发现
- 主要结局为偏头痛发作频率、严重程度和持续时间的变化,以及血清CRP、TAC、NO、MDA和SOD水平。
- 次要结局包括心理健康、睡眠质量和生活质量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Migraine is a severe neurological disorder that is recognized as one of the most common debilitating diseases worldwide. Although the exact cause of migraine is not known, research suggests that inflammation, oxidative stress, mitochondrial dysfunction, and insufficient nutrients may contribute to its development. Studies indicate that nutrition-based approaches are safer and more cost-effective strategies for managing migraine symptoms compared to medication. In this regard, the impact of nutrition, as a complementary medicine, is largely attributed to that of certain nutrients on inflammation and mitochondrial function. It is hypothesized that alpha-linolenic acid and L-carnitine, which possess anti-inflammatory and antioxidant properties, may be synergically beneficial for migraine patients. Therefore, this study will be conducted to assess the efficacy of alpha-linolenic acid and L-carnitine co-supplementation in patients with migraine. METHODS: This is a parallel, randomized, triple-blind, placebo-controlled clinical trial, in which 80 women aged 20 to 50 years with migraine will be assigned to receive either intervention group (n = 40) receiving both 1000 mg/day flaxseed oil and 500 mg/day L-carnitine simultaneously for 12 weeks, or control group (n = 40) receiving both 1000 mg/day paraffin oil and 500 mg/day maltodextrin as the placebos for the same duration. The primary outcomes include changes in clinical symptoms of migraine, including frequency, severity, and duration of attacks, serum levels of C-reactive protein (CRP), total antioxidant capacity (TAC), nitric oxide (NO), malondialdehyde (MDA), and superoxide dismutase (SOD). Secondary outcomes include mental health, sleep quality, and quality of life (QOL). DISCUSSION: In this study, we aim to investigate the potential benefits of combining alpha-linolenic acid and L-carnitine as a treatment option for migraine sufferers. Migraine, characterized by recurrent severe headaches, affects a significant portion of the population and can significantly impact an individual's quality of life. By studying alternative therapies such as alpha-linolenic acid and L-carnitine, researchers hope to expand the range of treatment options available and potentially provide relief to migraine sufferers. TRIAL REGISTRATION: Iranian Registry of Clinical Trials ( www.irct.ir ) (ID: IRCT20121216011763N57). Registration date: 29 March 2023. TRIAL STATUS: The protocol is version 1.0 dated December 30, 2023. Recruitment began on July 10, 2023, and is expected to be completed by January 22, 2024.
引用
- Golpour-Hamedani S, Bagherniy M, Khorvash F, et al. Investigating the effects of co-supplementation with alpha-linolenic acid and L-carnitine on inflammatory status, oxidative stress, clinical symptoms, mental health and quality of life in women with migraine: a protocol for a randomized, triple-blind, placebo-controlled trial. Trials. 2024. PMID: 39380085. doi:10.1186/s13063-024-08500-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。